Verve Therapeutics, Inc.
vervetx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 14, 2025. Its latest SEC filing is a SCHEDULE 13G from Aug 14, 2025.
10-Q for Q1 FY2025, filed May 14, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops single-course gene-editing medicines for people with inherited or established cardiovascular disease, designed to lower blood fats by changing genes in the liver.
10-K for FY2024, filed Feb 27, 2025
Who Were Their Customers?
Verve's named collaboration counterparties are Lilly and Vertex; their agreements cover licenses to product candidates and research and development work.
10-K for FY2024, filed Feb 27, 2025
Did Revenues Turn Into Profits?
No. It lost $198.7M in .
10-K for FY2024, filed Feb 27, 2025
−$228.7MView ↗
10-K for FY2024, filed Feb 27, 2025
−$198.7MView ↗
10-K for FY2024, filed Feb 27, 2025
−$161.4MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed May 14, 2025
−$31MView ↗
- ▼ −36% (Loss)
- vs −$48.7M in Q1 FY2024
-
Jul 25, 2025
Lilly completed its acquisition of Verve
Verve became an indirect wholly owned subsidiary of Lilly after the merger.
Sources
8-K, filed Jul 25, 2025
As a result of the consummation of the Offer and the consummation of the Merger in accordance with Section 251(h) of the DGCL on July 25…View ↗
Who Did They Compete With?
Competes with Amgen, Sanofi, Regeneron, Novartis, Lib Therapeutics, Merck &, AstraZeneca, Scribe Therapeutics, YolTech Therapeutics, Arrowhead, Lilly, CRISPR, Ionis Pharmaceuticals, and Silence Therapeutics
10-K for FY2024, filed Feb 27, 2025There are several approved products for LDL-C lowering or cardiovascular risk reduction, such as statins, ezetimibe, bempedoic acid…View ↗
Loading...
